Factors affecting toxicity, response and progression-free survival in relapsed patients with indolent B-cell lymphoma and mantle cell lymphoma treated with rituximab: a Japanese phase II study.
about
Phase I study of radioimmunotherapy with an anti-CD20 murine radioimmunoconjugate ((90)Y-ibritumomab tiuxetan) in relapsed or refractory indolent B-cell lymphoma.Veltuzumab (humanized anti-CD20 monoclonal antibody): characterization, current clinical results, and future prospects.Prevention of hepatitis B virus reactivation under rituximab therapy.Subcutaneous immunoglobulin in lymphoproliferative disorders and rituximab-related secondary hypogammaglobulinemia: a single-center experience in 61 patients.A new frontier in haematology - combining pharmacokinetic with pharmacodynamic factors to improve choice and dose of drugPruritus in patients treated with targeted cancer therapies: systematic review and meta-analysisModel-based design of rituximab dosage optimization in follicular non-Hodgkin's lymphoma.Reactivation of hepatitis B virus with rituximab.Rituximab serum concentrations during immuno-chemotherapy of follicular lymphoma correlate with patient gender, bone marrow infiltration and clinical responseMulticenter phase 1 trial of intraventricular immunochemotherapy in recurrent CNS lymphomaPhase I study of chimeric anti-CD20 monoclonal antibody in Chinese patients with CD20-positive non-Hodgkin's lymphomaRationale for optimal obinutuzumab/GA101 dosing regimen in B-cell non-Hodgkin lymphoma.Treatment of follicular lymphoma: current status.Influence of FCGRT gene polymorphisms on pharmacokinetics of therapeutic antibodies.Rituximab therapy in nephrotic syndrome: implications for patients' management.Rituximab biosimilars.The preclinical discovery of rituximab for the treatment of non-Hodgkin's lymphoma.Therapeutic drug monitoring of monoclonal antibodies in inflammatory and malignant disease: Translating TNF-α experience to oncology.Optimizing drug development in oncology by clinical trial simulation: Why and how?Development of a drug-disease simulation model for rituximab in follicular non-Hodgkin's lymphoma.Rituximab and other emerging monoclonal antibody therapies for lymphoma.Bevacizumab Pharmacokinetics Influence Overall and Progression-Free Survival in Metastatic Colorectal Cancer Patients.Rituximab in B-Cell Hematologic Malignancies: A Review of 20 Years of Clinical Experience.Rituximab monotherapy with eight weekly infusions for relapsed or refractory patients with indolent B cell non-Hodgkin lymphoma mostly pretreated with rituximab: a multicenter phase II study.Influence of FCGR3A-158V/F Genotype and Baseline CD20 Antigen Count on Target-Mediated Elimination of Rituximab in Patients with Chronic Lymphocytic Leukemia: A Study of FILO Group.Phase I study of LY2469298, an Fc-engineered humanized anti-CD20 antibody, in patients with relapsed or refractory follicular lymphoma.
P2860
Q33369667-F731BB9E-0271-4446-A263-922C4474965AQ33388543-A9751C90-8DF5-431E-B1AE-B8B3B536A8A9Q33390799-84DF26CE-4AAC-4DC7-BCAB-9C523DA67AE5Q33695997-04907F31-CD0B-4636-B0A7-BDEF4BC00A14Q34065271-D0B76797-B5A2-4F84-9B1D-A06E6B0126ACQ34272887-AD69EB90-D4BD-4F69-B711-FB357A2996BBQ36036378-8DFBFA15-0F5C-42E2-BA47-7604DA8F89CBQ36150595-C7A82731-91B7-4D14-8F01-E57290998BF1Q36216264-AF9EE0C1-D04C-4642-ACA7-6AD75C2F1F4AQ36584818-F54DE53A-5E3F-4635-ACD6-E5E9C182503AQ36897238-3B711417-121B-4452-931D-51081E514781Q37079029-EDCA8561-DC02-4A2A-B498-D570C3EBF85CQ37280915-7B4F34AA-5608-4B35-930E-C277AF4BB947Q37530222-A558C284-0EA0-42EE-83AE-31057E3D850DQ38075787-54E2E8DD-A92F-4B57-86AC-0AAEC2910CA2Q38100232-2D02016C-8CB3-4D7F-AC24-C146AFF0E6B2Q38530254-BE7E211C-517C-4F71-97D0-89FA0BEEBA89Q38564877-EEEB0842-EC31-4FD3-ADDA-826D1B028C19Q38675644-068B06D9-ED44-4C48-B2D9-F50953AF650EQ39937143-6746ACDB-DBFA-4E8D-8E9F-42DBC1B8D843Q40409351-685B3217-56D4-4ECA-AE31-BB8B93CEE5C5Q40533983-1E30F3E4-0CCC-4DDC-A2E6-C0DD5FE58A0FQ46675870-70DF352D-CA58-457D-9BB9-F74F915D2373Q51028994-49C85CFC-ED48-423E-9480-E0EF3B0F1D75Q51749848-70438AF8-A061-4994-9CA8-74BB83A3B0E8Q53278107-DFA19F0A-A93B-4190-A9C3-E9B8E6DB9E51
P2860
Factors affecting toxicity, response and progression-free survival in relapsed patients with indolent B-cell lymphoma and mantle cell lymphoma treated with rituximab: a Japanese phase II study.
description
2002 nî lūn-bûn
@nan
2002 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2002 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2002年の論文
@ja
2002年論文
@yue
2002年論文
@zh-hant
2002年論文
@zh-hk
2002年論文
@zh-mo
2002年論文
@zh-tw
2002年论文
@wuu
name
Factors affecting toxicity, re ...... ab: a Japanese phase II study.
@ast
Factors affecting toxicity, re ...... ab: a Japanese phase II study.
@en
type
label
Factors affecting toxicity, re ...... ab: a Japanese phase II study.
@ast
Factors affecting toxicity, re ...... ab: a Japanese phase II study.
@en
prefLabel
Factors affecting toxicity, re ...... ab: a Japanese phase II study.
@ast
Factors affecting toxicity, re ...... ab: a Japanese phase II study.
@en
P2093
P2860
P356
P1433
P1476
Factors affecting toxicity, re ...... ab: a Japanese phase II study.
@en
P2093
IDEC-C2B8 Study Group in Japan
M Taniwaki
S Nakamura
T Igarashi
P2860
P304
P356
10.1093/ANNONC/MDF155
P577
2002-06-01T00:00:00Z